Abstract:
The antimelancholic medicine or health products prepared with jujuba cAMP materials and the preparative method are provided in the present invention.

Description:
FIELD OF THE INVENTION 
       [0001]    The present invention relates to a medicine or a healthcare product prepared from jujuba cyclic adenosine monophosphate (jujuba cAMP) material for treating depression (melancholia). Furthermore, the present invention relates to a preparation method of the medicine or the healthcare product from the jujuba cAMP material for treating depression. 
       BACKGROUND OF THE INVENTION 
       [0002]    Depression is a common disease. According to statistics, about 25% females in the global population bad been experiencing depression in their lives, and about 10% males had been experiencing depression (referring to  Modern Psychology  written by Ch&#39;un-Hsing Chang). World Health Organization (WHO) published, “The incidence of depression in the world is about 11%. At present, there are about 340 million psychological depressed patients in the world, and the number is increasing. It is found in the investigation that depression will increase to be the number two common disease in the world from now on to 20 years later.” 
         [0003]    At present, anti-depression pharmaceuticals consist mainly Prozac, Paxil and Zoloft, etc., which belong to selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRT), and norepinephrine and dopamine reuptake inhibitor (NDRI), inhibiting the uptake of 5-hydroxytryptamine (5-HT), norepinephrine (NE) and dopamine (DA). The mechanism by which these pharmaceuticals function is by increasing the amount of human neurotransmitters such as 5-HT so as to decrease and alleviate the symptoms of depression. 
         [0004]    However, these pharmaceuticals have various side effects of different severities, such as increased suicide rate, headache, giddiness, vertigo, insomnolence, hypersomnia, tinnitus, thirsty, apocleisis, orexis, increased body weight, increased blood pressure, stomach upset, regurgitation nausea, emesis, dyspepsia, diarrhea, constipation, leg pain, skin rash, dither, convulsions, hyperhidrosis, edema, sexual appetite, impotence, etc. In recent years, the depression pharmaceuticals, such as Prozac, etc., had become a serious social problem. In 2004, the Food and Drug Administration (FDA) of the United States further mandated the pharmaceutical companies to revise product labels to clearly state the side effects and cautions in the instructions of 32 major anti-depression pharmaceuticals in the market, and emphasized to physicians and nurses that these pharmaceuticals might increase children&#39;s and adolescents&#39; suicide rate. Among them, Paxil was even found to be harmful in 1996, and has been recalled continually from the market since 2001. In June 2004, the New York State Attorney General accused GlaxoSmithKline Company of the Great Britain of beguilingly concealing the research report of the linkage between Paxil and “increased risk of suicidal behavior and tendencies in adolescents.” In light of the current situation, the search for a new generation of pharmaceuticals with fewer side effects and more pronounced/potent anti-depression qualities has become the center of attention of the entire pharmaceutical world. 
         [0005]    It is therefore attempted by the applicant to deal with the above situation encountered in the prior art. 
       SUMMARY OF THE INVENTION 
       [0006]    The purpose of the present invention is to provide a medicine or a healthcare product prepared from material containing jujuba cAMP for treating depression to overcome the insufficiency of the present technology. In particular, the invention provides new technical schemes that avoid the side effects of the present anti-depression medicine. 
         [0007]    Another purpose of the present invention is to provide the preparation method of the medicine or the healthcare product from the material containing jujuba cAMP for treating depression. 
         [0008]    The resolving scheme of the pharmaceutical of the present invention is the result endeavored by the inventor. The resolving scheme combines the theories of modern medicine and pharmacology. In particular, the resolving scheme combines the research fields of adenylate cyclase (AC)—cyclic adenosine monophosphate (cAMP) signaling transduction pathway, and cAMP-inducing transcription process, and more. The inventor endeavors in the research of the traditional botanical materials for treating depression. After much animal experimentation, the research has proven that jujuba cAMP, being the extrinsic non-hydrolyzable cAMP, can participate in the cAMP metastatic process of the organism, and simulate the enzyme function to increase cAMP in the cells, thus achieves the anti-depression effect. Jujuba cAMP is extracted from the daily edible fruit, jujuba. In the long history of human daily consumption of jujuba as fruit and as Chinese herbal medicine materials, there has been no harmful reaction case associated with taking jujuba, in contrast to the present anti-depression pharmaceuticals that have many undesirable side effects. After the inventor extracts jujuba containing a trace amount of jujuba cAMP (about one in ten thousand) by water, the inventor further purifies the jujuba water extract into the jujuba extract containing 1% of jujuba cAMP. The jujuba extract thus processed is tested in the animal experiment for anti-experimental depression function, and the result demonstrates that the jujuba extract has anti-experimental depression function. In contrast, the jujuba water extract that has not been further purified to increase the concentration of jujuba cAMP, while containing a trace amount of jujuba cAMP, does not have obvious anti-experimental depression function when the normal pharmaceutical dose is proceeded in the animal experiment testing for the anti-experimental depression function. Therefore, the invention submits the new technical scheme of manufacturing a pharmaceutical from the raw material of jujuba cAMP for treating depression, so as to improve the insufficiency in the prior art. 
         [0009]    Jujuba cAMP: 
         [0010]    Source: the dried matured fruit of  Zizyphus jujuba  Mill. 
         [0011]    Synonym: 3′,5′-cyclic adenosine monophosphate or 3′,5′-cyclic phosphate. 
         [0012]    English name: cyclic adenosine-3′,5′-monophosphate. 
         [0013]    Molecular formula and relative molecular weight: C 10 H 13 N 5 O 6 P.H 2 O and 347.23 respectively. 
         [0014]    Biological activity: The activity of cAMP-like material in jujuba is similar with that of cAMP. cAMP being the extrinsic non-hydrolyzable cAMP can simulate the enzyme function to increase cAMP in the cells. 
         [0015]    Structural formula: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0016]    In accordance with one aspect of the present invention, a medicine for treating depression is provided. The medicine includes jujuba cAMP. 
         [0017]    Preferably, the medicine is manufactured as an oral medicine. 
         [0018]    Preferably, the medicine has a dosage form being one selected from a group consisting of a tablet, a capsule, a powder, a pill, a dust, a solution, a microcapsule, a suspension, an emulsion, a particle, a dropping pill and a roll. 
         [0019]    Preferably, the dosage form is a first oral dosage form for taking once per day and has 0.003 mg to 0.3 mg of jujuba cAMP. Preferably, the first oral dosage form has 0.01 mg to 0.25 mg of jujuba cAMP. 
         [0020]    Preferably, the dosage form is a second oral dosage form for taking twice per day and has 0.002 mg to 0.2 mg of jujuba cAMP. Preferably, the second oral dosage form has 0.005 mg to 0.12 mg of jujuba cAMP. 
         [0021]    Preferably, the dosage form is a third oral dosage form for taking thrice per day and has 0.001 mg to 0.1 mg of jujuba cAMP. Preferably, the third oral dosage form has 0.003 mg to 0.08 mg of jujuba cAMP. 
         [0022]    Preferably, the dosage form is a fourth oral dosage form for taking four times per day and has 0.0008 mg to 0.06 mg of jujuba cAMP. Preferably, the fourth oral dosage form has 0.002 mg to 0.04 mg of jujuba cAMP. 
         [0023]    Preferably, the medicine according to claim  1  further includes at least one of a pharmacologically acceptable carrier and an additive. 
         [0024]    Preferably, the medicine is manufactured as a healthcare product or a nutrient supplement. 
         [0025]    Preferably, jujuba cAMP is extracted from jujuba. 
         [0026]    Preferably, jujuba is extracted for obtaining a first extract having a first jujuba cAMP concentration, the first extract is further extracted for obtaining a second extract having a second jujuba cAMP concentration, the second jujuba cAMP concentration is higher than the first jujuba cAMP concentration, and the second extract is a raw material in the medicine. 
         [0027]    In accordance with another aspect of the present invention, a preparation method of jujuba cAMP of a medicine for treating depression is provided. The preparation method comprises steps of (a) extracting jujuba for obtaining a first extract having a first jujuba cAMP concentration; and (b) purifying the first extract for obtaining a second extract having a second jujuba cAMP concentration. The second jujuba cAMP concentration is higher than the first jujuba cAMP concentration. 
         [0028]    Preferably, the step (b) is processed by chromatographing the first extract with a macroporous resin bound with an aldehyde group. 
         [0029]    Preferably, the step (b) further comprises steps of (b1) chromatographing the first extract with an OU-2 macroporous resin bound with the aldehyde group; and (b2) chromatographing the first extract with an ME-2 macroporous resin bound with the aldehyde group. 
         [0030]    In accordance with another aspect of the present invention, a method for preparing jujuba cAMP is provided. The method includes steps of (a) extracting jujuba for obtaining a first extract; and (b) chromatographing the first extract with a macroporous resin having an aldehyde group bound thereon. 
         [0031]    The above objectives and advantages of the present invention will become more readily apparent to those ordinarily skilled in the art after reviewing the following detailed descriptions and accompanying drawings, in which: 
     
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         [0032]      FIG. 1  is a flowchart showing a preparation method of a medicine in accordance with a first preferred embodiment of the present invention; 
           [0033]      FIG. 2  is a flowchart showing a preparation method of a medicine in accordance with a second preferred embodiment of the present invention; 
           [0034]      FIG. 3  is a flowchart showing a preparation method of a medicine in accordance with a third preferred embodiment of the present invention; 
           [0035]      FIG. 4  is a flowchart showing a preparation method of a medicine in accordance with a fourth preferred embodiment of the present invention; 
           [0036]      FIG. 5  is a flowchart showing a preparation method of a medicine in accordance with a fifth preferred embodiment of the present invention; 
           [0037]      FIG. 6  is a flowchart showing a preparation method of a medicine in accordance with a sixth preferred embodiment of the present invention; and 
           [0038]      FIG. 7  is a flowchart showing a preparation method of a medicine in accordance with a seventh preferred embodiment of the present invention. 
       
    
    
     DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT 
       [0039]    The present invention will now be described more specifically with reference to the following embodiments. It is to be noted that the following descriptions of preferred embodiments of this invention are presented herein for purpose of illustration and description only; it is not intended to be exhaustive or to be limited to the precise form disclosed. 
         [0040]    In order to accomplish the purpose of the present invention, the technical schemes of the present invention are particularly provided as follows. 
       Example 1 
       [0041]    The oral medicine of the present invention for treating depression is manufactured from the material including jujuba cAMP. 
       Example 2 
       [0042]    The raw material including jujuba cAMP is manufactured as any pharmacologically common oral medicine dosage form of the present invention, such as tablet, capsule, powder, pill, dust, solution, microcapsule, suspension, emulsion, particle, dropping pill, and roll, etc., for treating depression. 
       Example 3 
       [0043]    The pharmaceutical of the present invention is manufactured from the raw material including 0.003˜0.3 mg of jujuba cAMP as a dosage form for taking once per day. Preferably, the pharmaceutical of the present invention is manufactured from the raw material including 0.01˜0.25 mg of jujuba cAMP as a dosage form for taking once per day. 
       Example 4 
       [0044]    The pharmaceutical of the present invention is manufactured from the raw material including 0.002˜0.2 mg of jujuba cAMP as a dosage form for taking twice per day. Preferably, the pharmaceutical of the present invention is manufactured from the raw material including 0.005˜0.12 mg of jujuba cAMP as a dosage form for taking twice per day. 
       Example 5 
       [0045]    The pharmaceutical of the present invention is manufactured from the raw material including 0.001˜0.1 mg of jujuba cAMP as a dosage form for taking thrice per day. Preferably, the pharmaceutical of the present invention is manufactured from the raw material including 0.003˜0.08 mg of jujuba cAMP as a dosage form for taking thrice per day. 
       Example 6 
       [0046]    The pharmaceutical of the present invention is manufactured from the raw material including 0.0008˜0.06 mg of jujuba cAMP as a dosage form for taking four times per day. Preferably, the pharmaceutical of the present invention is manufactured from the raw material including 0.002˜0.04 mg of jujuba cAMP as a dosage form for taking four times per day. 
       Example 7 
       [0047]    After jujuba is fractured, the fractured jujuba is soaked in the water at room temperature, and then the soaked jujuba undergoes decoction and alcohol sedimentation for obtaining the jujuba extract, which is further absorbed, sequentially separated by the OU-2 and ME-2 macroporous resins and dried. Finally, the jujuba extract containing high concentration of jujuba cAMP is obtained to be the raw material for preparing the pharmaceutical of the present invention. 
       Example 8 
       [0048]    The oral medicine of the present invention can include the pharmacologically acceptable carriers, additives and the composition thereof. 
       Example 9 
       [0049]    The oral medicine of the present invention can be further manufactured as healthcare product and nutrient supplements. 
         [0050]    In order to accomplish the purpose of the present invention, the preparation methods of the pharmaceutical is provided as follows. 
         [0051]    Method 1: 
         [0052]    In accordance with the pharmaceutical standard method of Good Manufacturing Practice (GMP), the oral medicine of the present invention for treating depression is manufactured from the raw material including jujuba cAMP. 
         [0053]    Method 2: 
         [0054]    In accordance with the pharmaceutical standard method of GMP, the raw material including jujuba cAMP is manufactured as any pharmacologically common oral medicine dosage form of the present invention, such as tablet, capsule, powder, pill, dust, solution, microcapsule, suspension, emulsion, particle, dropping pill, and roll, etc., for treating depression. 
         [0055]    Method 3: 
         [0056]    In accordance with the pharmaceutical standard method of GMP, the pharmaceutical of the present invention is manufactured from the raw material including 0.003˜0.3 mg of jujuba cAMP as a dosage form for taking once per day. Preferably, the pharmaceutical of the present invention is manufactured from the raw material including 0.01˜0.25 mg of jujuba cAMP as a dosage form for taking once per day. 
         [0057]    Method 4: 
         [0058]    In accordance with the pharmaceutical standard method of GMP, the pharmaceutical of the present invention is manufactured from the raw material including 0.002˜0.2 mg of jujuba cAMP as a dosage form for taking twice per day. Preferably, the pharmaceutical of the present invention is manufactured from the raw material including 0.005˜0.12 mg of jujuba cAMP as a dosage form for taking twice per day. 
         [0059]    Method 5: 
         [0060]    In accordance with the pharmaceutical standard method of GMP, the pharmaceutical of the present invention is manufactured from the raw material including 0.001˜0.1 mg of jujuba cAMP as a dosage form for taking thrice per day. Preferably, the pharmaceutical of the present invention is manufactured from the raw material including 0.003˜0.08 mg of jujuba cAMP as a dosage form for taking thrice per day. 
         [0061]    Method 6: 
         [0062]    In accordance with the pharmaceutical standard method of GMP, the pharmaceutical of the present invention is manufactured from the raw material including 0.0008˜0.06 mg of jujuba cAMP as a dosage form for taking four times per day. Preferably, the pharmaceutical of the present invention is manufactured from the raw material including 0.002˜0.04 mg of jujuba cAMP as a dosage form for taking four times per day. 
         [0063]    Method 7: 
         [0064]    In accordance with the pharmaceutical standard method of GMP, after jujuba is fractured, the fractured jujuba is soaked in the water at room temperature, and then the soaked jujuba is extracted by decoction and alcohol sedimentation for obtaining the jujuba extract, which is further absorbed, sequentially separated by the OU-2 and ME-2 macroporous resins and dried. Finally, the jujuba extract containing high concentration of jujuba cAMP is obtained to be the raw material for preparing the pharmaceutical of the present invention. 
         [0065]    Method 8: 
         [0066]    In accordance with the pharmaceutical standard method of GMP, the oral medicine of the present invention can include the pharmacologically acceptable carriers, additives and the composition thereof. 
         [0067]    Method 9: 
         [0068]    In accordance with the pharmaceutical standard method of GMP, the oral medicine of the present invention can be further manufactured as healthcare product and nutrient supplements. 
       THE PREFERRED EMBODIMENT 
       [0069]    The present invention is further illustrated as follows by combining the figures and the preferred embodiments. 
       Embodiment 1 
       [0070]    Please refer to  FIG. 1 , which is the flowchart showing a preparation method of a medicine in accordance with a first preferred embodiment of the present invention. In  FIG. 1 , in accordance with the pharmaceutical standard method of GMP, 30 g of the prepared jujuba extract having 1% jujuba cAMP is the raw material (step  101 ). Two hundred seventy (270) g of the adjuvant and the excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to manufacture the tablet dosage form (10,000 tablets, 30 mg/tablet and 0.03 mg jujuba cAMP per tablet) of the oral medicine or the healthcare product of the present invention for treating depression (steps  102  and  103 ). 
       Embodiment 2 
       [0071]    Please refer to  FIG. 2 , which is the flowchart showing a preparation method of a medicine in accordance with a second preferred embodiment of the present invention. In  FIG. 2 , in accordance with the pharmaceutical standard method of GMP, 30 g of the prepared jujuba extract having 1% jujuba cAMP is the raw material (step  201 ). Four hundred twenty (420) g of the adjuvant and the excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to manufacture the tablet dosage form (15,000 tablets, 30 mg/tablet and 0.02 mg jujuba cAMP per tablet) of the oral medicine or the healthcare product of the present invention for treating depression (steps  202  and  203 ). 
       Embodiment 3 
       [0072]    Please refer to  FIG. 3 , which is the flowchart showing a preparation method of a medicine in accordance with a third preferred embodiment of the present invention. In  FIG. 3 , in accordance with the pharmaceutical standard method of GMP, 50 g of the prepared jujuba extract having 1% jujuba cAMP is the raw material (step  301 ). Two hundred fifty (250) g of the adjuvant and the excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to manufacture the tablet dosage form (10,000 tablets, 30 mg/tablet and 0.05 mg jujuba cAMP per tablet) of the oral medicine or the healthcare product of the present invention for treating depression (steps  302  and  303 ). 
       Embodiment 4 
       [0073]    Please refer to  FIG. 4 , which is the flowchart showing a preparation method of a medicine in accordance with a fourth preferred embodiment of the present invention. In  FIG. 4 , in accordance with the pharmaceutical standard method of GMP, 30 g of the prepared jujuba extract having 1% jujuba cAMP is the raw material (step  401 ). Two hundred ten (210) g of the adjuvant and the excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to manufacture the tablet dosage form (12,000 tablets, 20 mg/tablet and 0.25 mg jujuba cAMP per tablet) of the oral medicine or the health food of the present invention for treating depression (steps  402  and  403 ). 
       Embodiment 5 
       [0074]    Please refer to  FIG. 5 , which is the flowchart showing a preparation method of a medicine in accordance with a fifth preferred embodiment of the present invention. In  FIG. 5 , in accordance with the pharmaceutical standard method of GMP, 17 g of the prepared jujuba extract having 1% jujuba CAMP is the raw material (step  501 ). One hundred eighty three (183) g of the adjuvant and the excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to manufacture the tablet dosage form (10,000 tablets, 20 mg/tablet and 0.17 mg jujuba cAMP per tablet) of the oral medicine or the healthcare product of the present invention for treating depression (steps  502  and  503 ). 
       Embodiment 6 
       [0075]    Please refer to  FIG. 6 , which is the flowchart showing a preparation method of a medicine in accordance with a sixth preferred embodiment of the present invention. In  FIG. 6 , in accordance with the pharmaceutical standard method of GMP, 13 g of the prepared jujuba extract having 1% jujuba cAMP is the raw material (step  601 ). One hundred eighty seven (187) g of the adjuvant and the excipient (such as starch, lactose, silicon dioxide and magnesium stearate, etc.) are added to manufacture the tablet dosage form (10,000 tablets, 20 mg/tablet, and 0.013 mg jujuba cAMP per tablet) of the oral medicine or the healthcare product of the present invention for treating depression (steps  602  and  603 ). 
       Embodiment 7 
       [0076]    Please refer to  FIG. 7 , which is the flowchart showing a preparation method of a medicine in accordance with a seventh preferred embodiment of the present invention. In  FIG. 7 , in accordance with the pharmaceutical standard method of GMP, after 10 kg jujuba (step  701 ) is fractured, the fractured jujuba is soaked in the water at room temperature, and then the soaked jujuba is extracted by decoction and alcohol sedimentation for obtaining the jujuba extract, which is further absorbed, sequentially separated by the OU-2 and ME-2 macroporous resins and dried, so as to obtain 30 g of the jujuba extract having jujuba cAMP (step  702 ). The jujuba extract having 1% (300 mg) jujuba cAMP is measured by high performance liquid chromatography (HPLC), so as to manufacture the oral medicine or the healthcare product of the present invention for treating depression (step  703 ). 
       Experiment 1: The Influence of Embodiment 3 in the Mouse Tail-Hanging Experiment 
       [0077]    1.1 Experimental animals: ICR mice, male, 22.0±2 g of body weight, secondary, are provided by the Experimental Animal Science Department of Capital Medical University, Beijing. 
         [0078]    1.2 Experiment pharmaceuticals: The pharmaceutical of Embodiment 3 is provided by Beijing Wonner Biotech. Ltd. Co., and Paroxetine (Paxil) is the product of Thong Mei Tianjin Smith Kline pharmaceuticals Co. Ltd. 
         [0079]    1.3 Experimental equipment: Stop watch. 
         [0080]    1.4 Dose designs: 1. High dose of Embodiment 3 (5 mg/kg/d); 2. middle dose of Embodiment 3 (2.5 mg/kg/d); and 3. low dose of Embodiment 3 (1.25 mg/kg/d). 
         [0081]    1.5 Experimental method and result: 
         [0082]    1.5.1 Group division and administration of drug: The mice are grouped randomly, with 10 mice per group. 1. High dose of Embodiment 3 (5 mg/kg, per oral (P.O.), administered for 7 days); 2. middle dose of Embodiment 3 (2.5 mg/kg, P.O., administered for 7 days); 3. low dose of Embodiment 3 (1.25 mg/kg, P.O., administered for 7 days); 4. Paroxetine (3 mg/kg, P.O., administered for 7 days); and 5. physiological saline (P.O.). After 1 hour of the last drug administration, the mouse tail-hanging experiment is proceeded. 
         [0083]    1.5.2 Experimental method: The mouse&#39;s tail (1 cm to the tail end) is taped on the wood strip higher than the platform for 5 cm and hung up for 6 minutes. The time of non-movement of the mouse for the last 5 minutes is recorded. 
         [0084]    1.5.3 Statistic calculation: The experimental data are represented as  X ±SD and the experimental result is calculated as analysis of variance (ANOVA) by SPSS 11.5 statistic software. 
         [0085]    1.5.4 Experimental result: Please refer to Table 1. 
         [0000]    
       
         
               
             
               
               
               
             
           
               
                 TABLE 1 
               
             
             
               
                   
               
               
                 The influence of Embodiment 3 on the time of non-movement of the 
               
               
                 mouse 
               
             
          
           
               
                   
                 Animal 
                   
               
               
                 Group 
                 number 
                 Time of non-movement (s) 
               
               
                   
               
               
                 Physiological saline (control) 
                 10 
                 122.18 ± 45.78   
               
               
                 Paroxetine 
                 10 
                 67.59 ± 39.09** 
               
               
                 High dose of Embodiment 3 
                 10 
                 75.13 ± 38.26** 
               
               
                 Middle dose of Embodiment 3 
                 10 
                 86.80 ± 48.08*  
               
               
                 Low dose of Embodiment 3 
                 10 
                 102.36 ± 13.68   
               
               
                   
               
               
                 In comparison with the control group: 
               
               
                 *P &lt; 0.05, and 
               
               
                 **P &lt; 0.01. 
               
             
          
         
       
     
         [0086]    Conclusion: According to the above experiment, it can be found that the high and middle doses of Embodiment 3 of the present invention and Paroxetine all decrease the time of non-movement after the mouse&#39;s tail is hung. The differences are significant in comparison with the physiological group (control). Therefore, the Embodiment 3 of the present invention having anti-experimental depression function can be extrapolated. 
       Experiment 2: The Influence of Embodiment 3 in the Mouse Swimming by Compulsion Experiment 
       [0087]    2.1 Experimental animals: ICR mice, male, 22.0±2 g body weight, secondary, are provided by the Experimental Animal Science Department of Capital Medical University, Beijing. 
         [0088]    2.2 Experiment pharmaceuticals: The pharmaceutical of Embodiment 3 is provided by Beijing Wonner Biotech. Ltd. Co., and Paroxetine (Paxil) is the product of Zhong Mei Tianjin Smith Kline pharmaceuticals Co. Ltd. 
         [0089]    2.3 Experimental equipments: Stop watch. 
         [0090]    2.4 Dose designs: 1. High dose of Embodiment 3 (5 mg/kg/d); 2. middle dose of Embodiment 3 (2.5 mg/kg/d); and 3. low dose of Embodiment 3 (1.25 mg/kg/d). 
         [0091]    2.5 Experimental method and result: 
         [0092]    2.5.1 Group division and administration of drug: The mice are grouped randomly, with 10 mice per group. 1. High dose of Embodiment 3 (5 mg/kg, P.O., administered for 7 days); 2. middle dose of Embodiment 3 (2.5 mg/kg, P.O., administered for 7 days); 3. low dose of Embodiment 3 (1.25 mg/kg, P.O., administered for 7 days); 4. Paroxetine (3 mg/kg, P.O., administered for 7 days); and 5. physiological saline (P.O.). 
         [0093]    2.5.2 Experimental method: After 1 hour of the last administration of drug, the mouse is placed in 25° C. water in the glass tank having 10 cm of the water depth and 14 cm of diameter. The accumulative time of non-movement of the mouse in the water for the last 5 minutes is recorded. 
         [0094]    2.5.3 Statistic calculation: The experimental data are represented as  X ±SD, and the experimental result is calculated as ANOVA by SPSS 11.5 statistic software. 
         [0095]    2.5.4 Experimental result: Please refer to Table 2. 
         [0000]    
       
         
               
             
               
               
               
             
           
               
                 TABLE 2 
               
             
             
               
                   
               
               
                 The result of time of non-movement in the mouse swimming by 
               
               
                 compulsion experiment 
               
             
          
           
               
                   
                 Animal 
                   
               
               
                 Group 
                 number 
                 Decreased temperature (° C.) 
               
               
                   
               
               
                 Physiological saline (control) 
                 10 
                 127.53 ± 41.80  
               
               
                 Paroxetine 
                 10 
                  83.42 ± 40.71* 
               
               
                 High dose of Embodiment 3 
                 10 
                  80.39 ± 40.89* 
               
               
                 Middle dose of Embodiment 3 
                 10 
                 87.60 ± 43.42 
               
               
                 Low dose of Embodiment 3 
                 10 
                 91.05 ± 47.21 
               
               
                   
               
               
                 In comparison with the control group: 
               
               
                 *P &lt; 0.05, and 
               
               
                 **P &lt; 0.01. 
               
             
          
         
       
     
         [0096]    Conclusion: According to the above experiment, it can be found that the high doses of Embodiment 3 of the present invention and Paroxetine all decrease the time of non-movement in the mouse swimming by compulsion test. Therefore, the Embodiment 3 of the present invention having anti-experimental depression function can be extrapolated. 
         [0097]    Industrial Usefulness: 
         [0098]    The application scopes of the oral medicine of the present invention for treating depression lie in that: 
         [0099]    1. the oral medicine described in the present invention for treating depression can include the pharmacologically acceptable additives; 
         [0100]    2. the oral medicine described in the present invention for treating depression can be manufactured as the known dosage forms, such as powder, capsule, and tablet, etc.; and 
         [0101]    3. the oral medicine described in the present invention for treating depression can be manufactured as the health food for treating depression. 
         [0102]    While the invention has been described in terms of what is presently considered to be the most practical and preferred Embodiments, it is to be understood that the invention needs not be limited to the disclosed Embodiments. On the contrary, it is intended to cover various modifications and similar arrangements included within the spirit and scope of the appended claims, which are to be accorded with the broadest interpretation so as to encompass all such modifications and similar structures.